The adverse prognostic effect of CDKN2A/B deletions, as well as the additive adverse prognostic effect in combination with TP53 deletions, was also confirmed in the international, randomized, phase III MCL Younger and MCL Elderly trials of the European MCL Network and in the Fondazione Italiana Linfomi V‐RBAC trial [20, 25]. Here, TP53 is linked to mantle cell lymphoma.